SCHEMBL6949240

SCHEMBL6949240

Cc1nc(N2CCc3ccccc3CC2)c([N+](=O)[O-])c(=O)n1CCCO

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.46
ALDH1A1 P00352 5/20 0.41
RXFP1 Q9HBX9 2/20 0.41
KDM4E B2RXH2 1/20 0.41
CYP2C9 P11712 2/20 0.39
CYP2D6 P10635 1/20 0.39
POLB P06746 4/20 0.38
MEN1 O00255 4/20 0.38
KMT2A Q03164 4/20 0.38
MAPT P10636 5/20 0.37
GPR55 Q9Y2T6 1/20 0.37
LMNA P02545 2/20 0.37
HTT P42858 2/20 0.37
THRB P10828 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2C19 P33261 1/20 0.36
GAA P10253 1/20 0.36
HTR1A P08908 1/20 0.36
HTR7 P34969 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6949181 0.97 TSHR (0.43) TSHRALDH1A1RXFP1KDM4ECYP2C9
SCHEMBL6953752 0.94 CYP2C9 (0.40) TSHRALDH1A1CYP2C9CYP2D6POLB
SCHEMBL6952822 0.91 CYP2C9 (0.39) TSHRCYP2C9CYP2D6POLBMEN1
SCHEMBL6952584 0.88 CYP2C9 (0.40) TSHRALDH1A1KDM4ECYP2C9CYP2D6
SCHEMBL6949137 0.88 CYP2D6 (0.44) ALDH1A1CYP2C9CYP2D6MEN1KMT2A
SCHEMBL6952859 0.87 CYP2C9 (0.40) ALDH1A1CYP2C9CYP2D6POLBMEN1
SCHEMBL6946348 0.86 MAPT (0.42) ALDH1A1CYP2C9CYP2D6POLBMEN1
SCHEMBL6950082 0.85 ALDH1A1 (0.39) ALDH1A1RXFP1KDM4ECYP2C9CYP2D6
SCHEMBL6954763 0.85 GAA (0.47) ALDH1A1KDM4ECYP2C9CYP2D6MEN1
SCHEMBL6950999 0.85 SPHK1 (0.36) TSHRCYP2C9CYP2D6POLBMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1074549-B1 Tetrahydro-benzo(d)azepines and their use as antagonists at metabotropic glutamate receptors HOFFMANN LA ROCHE (CH) 2003-11-19 EP disclosed
US-6218385-B1 FOR THERAPY OR PROPHYLAXIS OF ACUTE AND/OR CHRONIC NEUROLOGICAL DISORDERS SUCH AS EPILEPSY, STROKE, CHRONIC AND ACUTE PAIN, PSYCHOSIS, SCHIZOPHRENIA, ALZHEIMER'S DISEASE, COGNITIVE DISORDERS AND MEMORY DEFICITS HOFFMANN-LA ROCHE INC. 2001-04-17 US disclosed
EP-1074549-A2 Tetrahydro-benzo(d)azepines and their use as antagonists at metabotropic glutamate receptors F. HOFFMANN-LA ROCHE AG (CH) 2001-02-07 EP disclosed